Dividends & Income
To screen ETFs by asset class, performance, yield and more, check out the
View as an RSS Feed
View Karine.sil's Comments
Johnson & Johnson's Real Answer To Imminent Decline In Sales Of Top-Selling Drug
Remicade maximized very significant growth this quarter and even though the patent expiration of Remicade affect the revenue of J & J in 2014, it is important to note that the pharmaceutical division of the company is very well positioned with many new drugs to market, at a time when the company isn't facing many expirations of other patent medicines.
We can still see better results in the coming quarters, considering the fact that even sales of Remicade "plummet" as the author mentioned, still has much work to be done, the results still appear consequently.
Dec 3, 2013. 01:09 AM
Link to Comment
Xignite quote data
© 2015 Seeking Alpha